Wetenschappelijke publicaties van Bordet

MRI-Targeted Prostate Fusion Biopsy: What Are We Missing outside the Target? Implications for Treatment Planning.

Oderda M, Dematteis A, Calleris G, Diamand R, Gatti M, Marra G, Adans-Dester G, Al Salhi Y, Pastore A, Faletti R, Gontero P

MRI-Targeted Prostate Fusion Biopsy: What Are We Missing outside the Target? Implications for Treatment Planning.

Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study.

Arecco L, Latocca MM, Blondeaux E, Riccardi F, Mocerino C, Guarneri V, Mioranza E, Bisagni G, Gasparini E, Puglisi F, Membrino A, Ferro A, Adamo V, Giovanardi F, Tamberi S, Donati S, Landucci E, Biganzoli L, Piccinini S, Pastorino S, de Azambuja E, Poggio F, Lambertini M, Del Mastro L

Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study.

International survey on invasive lobular breast cancer identifies priority research questions.

Oesterreich S, Pate L, Lee AV, Chen F, Jankowitz RC, Mukhtar R, Metzger O, Sikora MJ, Li CI, Sotiriou C, Shah OS, Koorman T, Ulaner G, Reis-Filho JS, Davidson NM, Van Baelen K, Hutcheson L, Freeney S, Migyanka F, Turner C, Derksen P, Bear T, Desmedt C

International survey on invasive lobular breast cancer identifies priority research questions.

Tumour Heterogeneity in Molecular Imaging for Breast Cancer.

Lobo-Martins S, Agostinetto E, de Azambuja E, Gebhart G

Tumour Heterogeneity in Molecular Imaging for Breast Cancer.

Lobo-Martins S, Agostinetto E, de Azambuja E, Gebhart G

Tumour Heterogeneity in Molecular Imaging for Breast Cancer.

Lobo-Martins S, Agostinetto E, de Azambuja E, Gebhart G

Tumour Heterogeneity in Molecular Imaging for Breast Cancer.

Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups.

Bardia A, Cortes J, Bidard FC, Neven P, Garcia-Saenz J, Aftimos P, O'Shaughnessy J, Lu J, Tonini G, Scartoni S, Paoli A, Binaschi M, Wasserman T, Kaklamani V

Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups.

Squamous cell carcinoma of the nail apparatus: Histopathology and immunohistochemistry correlation study.

Moulart F, Olemans C, de Saint Aubain N, Richert B, André J

Squamous cell carcinoma of the nail apparatus: Histopathology and immunohistochemistry correlation study.

Communication and support of patients and caregivers in chronic cancer care: ESMO Clinical Practice Guideline.

Stiefel F, Bourquin C, Salmon P, Achtari Jeanneret L, Dauchy S, Ernstmann N, Grassi L, Libert Y, Vitinius F, Santini D, Ripamonti CI

Communication and support of patients and caregivers in chronic cancer care: ESMO Clinical Practice Guideline.

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Bordet